MG
ADPT icon

Mather Group’s Adaptive Biotechnologies ADPT Stock Holding History

Mather Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5K Sell
1,095
-2,445
-69% -$37.5K ﹤0.01% 1292
2026
Q1 		$49.1K Buy
+3,540
New +$56.4K ﹤0.01% 1064
2024
Q3 		– Sell
-30
Closed -$96 – 1714
2024
Q2 		$96 Buy
+30
New +$95 ﹤0.01% 2150

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mather Group's ADPT Position: Q2 2026 in Review

Mather Group reduced its Adaptive Biotechnologies (ADPT) stake by 69% in Q2 2026, selling an estimated $37.5K and leaving 1,095 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

Mather Group first reported a position in ADPT in Q2 2024 and has held it in 3 quarters since. The position peaked at $49.1K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Mather Group held 1,095 shares of Adaptive Biotechnologies worth $23.5K as of Q2 2026.
  • Mather Group sold 2,445 Adaptive Biotechnologies shares in Q2 2026, an estimated $37.5K.
  • Adaptive Biotechnologies made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1292 holding.
  • Mather Group first reported a position in Adaptive Biotechnologies in Q2 2024 and has held it in 3 quarters since.
  • Mather Group's Adaptive Biotechnologies position peaked at $49.1K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.